🇺🇸 US Stock Screener ← Switch market ⚡ HerAI

Eli Lilly and Company LLY SPXR3KPHARMA

Healthcare · Drug Manufacturers - General · United States
https://www.lilly.com
Company Profile ↓
$1,306.69
+99.24% 1Y
Mkt Cap$1.16T
P/E43.95
P/B30.34
Div. Yield0.60%
52W High$1,306.69
52W Low$655.85
Book Value$38.00
EPS (TTM)$29.73

Company Overview

Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, such as Cyramza for the second-line treatment of gastric cancer or gastro-esophageal junction adenocarcinoma; Erbitux for colorectal cancers and head and neck cancers; Inluriyo for breast cancer; Jaypirca for chronic lymphocytic leukemia or small lymphocytic lymphoma; Retevmo for the treatment of metastatic NSCLC; TYVYT for classic hodgkin's lymphoma; and Verzenio for breast cancer. In addition, the company offers immunology products, which include Ebglyss; Olumiant; Omvoh; and Taltz. Further, it provides Emgality for migraine prevention and episodic cluster headache; and Kisubla for symptomatic Alzheimer's disease. The company has collaborations with Boehringer Ingelheim Pharmaceuticals, Inc. for the Jardiance product family; and F. Hoffmann-La Roche Ltd and Genentech, Inc. for lebrikizumab, as well as license agreements with Almirall, S.A. for Ebglyss; and Chugai Pharmaceutical Co., Ltd for orforglipron; strategic collaboration with Ascidian Therapeutics for development of therapies for undisclosed monogenic kidney diseases; BioArctic AB (publ) for new treatment; QurCan Therapeutics Inc for development of PLNP-enabled genetic medicine therapeutics for the treatment of central nervous system and peripheral nervous system; and Abbisko Therapeutics for discovery and development of medicines across multiple targets. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Why Investors Should Care

Strong Return on Equity

Generates a return on equity of 102.3%, reflecting efficient use of shareholder capital.

Consistent Profit Growth

Net profit has compounded at 11.4% per year over the last five years.

Healthy Margins

Maintains a net profit margin of 33.5%.

Positive Free Cash Flow

Generates positive free cash flow, funding growth and shareholder returns internally.

Recent Developments

  • Dec 2025 Revenue of $65.18B (+44.7% YoY); net profit $20.64B.
  • Trailing 12 Months Year-on-year growth — revenue +47.7%, earnings +26.2%.
  • 5-Year Trend Long-term compounding — revenue CAGR 7.2%, profit CAGR 11.4%.

Growth & Price Performance

Compounded Sales Growth

5 Years:7.20%
1 Year:47.70%

Compounded Profit Growth

5 Years:11.41%
1 Year:26.20%

Stock Price Performance

1 Year:+99.24%
6 Months:+42.84%
3 Months:+9.41%
1 Month:+13.53%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bullish
52-Week Range 100% of range
$655.85 $1,306.69
Trend Signals
  • Price vs 50-DMAAbove
  • Price vs 200-DMAAbove
  • RSI (14)70.74 · Overbought
Price Performance
1M+13.53%
3M+9.41%
6M+42.84%
1Y+99.24%
Valuation vs Sector

P/E of 43.95 is above the sector median of 25.61 — pricier than peers.

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Strong return on equity of 102.3%.
  • Excellent profit margin of 33.5%.
  • Profit CAGR of 11.4% over 5 years.
  • Generates positive free cash flow.
  • In a confirmed uptrend (50-DMA above 200-DMA).

CONS

No notable concerns flagged.

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
43.95
Industry PE
25.61
Forward P/E
27.60
PEG Ratio
1.12
Book Value
$38.00
Price to Book
30.34
P/S
12.90
EV/EBITDA
25.74
Dividend Yield
0.60%

Growth (CAGR)

Revenue 5Y
7.20%
Profit 5Y
11.41%
Revenue (YoY)
47.70%
Earnings (YoY)
26.20%

Profitability & Returns

ROCE
-
ROE
102.29%
ROA
20.36%
Profit Margin
33.53%
Op Margin
54.22%
Gross Margin
83.40%
EPS (Latest Qtr)
$7.94
EPS (TTM)
$29.73

Balance Sheet & Liquidity

Debt/Equity
1.62
Quick Ratio
0.68
Current Ratio
1.35
Debt
$54.91B
Total Assets
$142.28B
Current Assets
-
Working Capital
-

Ownership

Promoter Holding
0.16%
Chg in Prom Hold
0.00%
FII / Inst Holding
85.32%
Chg in FII Hold
-0.00%

Financial Snapshot

Enterprise Value
$1.16T
Total Revenue (TTM)
$79.67B
EBITDA
$41.71B
Free Cash Flow
$11.07B
Operating Cash Flow
$28.08B
Shares Outstanding
891.36M
Gross Margin
83.40%
Payout Ratio
21.69%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP $P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 LLY Eli Lilly and Company SPXR3KPHARMA 1,306.69 43.95 $1.16T 0.60% - 102.29% 7.20% 11.41%
2 JNJ Johnson & Johnson SPXR3KPHARMA 267.61 31.05 $644.91B 1.98% 14.88% 25.74% 2.43% 4.76%
3 ABBV AbbVie Inc. SPXR3KPHARMA 285.19 80.56 $503.96B 2.54% 10.47% -129.24% 1.75% -29.06%
4 UNH UnitedHealth Group Incorporated SPXR3KPHARMA 424.98 27.29 $381.46B 2.47% 9.74% 14.15% 10.40% 5.43%
5 MRK Merck & Co., Inc. SPXR3KPHARMA 147.24 117.79 $363.27B 2.31% - 6.96% 5.64% 10.01%
6 NVS Novartis AG PHARMA 156.27 23.61 $297.02B 3.36% 21.09% 30.35% 9.25% 26.22%
7 AZN AstraZeneca PLC NDXPHARMA 172.57 25.80 $267.64B 2.00% 15.97% 21.96% 9.82% 45.96%
8 TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA 676.54 36.45 $250.15B 0.29% 8.14% 13.51% 8.81% 12.95%
9 AMGN Amgen Inc. NDXSPXR3KPHARMA 447.28 27.78 $241.81B 2.44% 13.95% 91.47% 5.51% 5.55%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric Mar 2015Jun 2015Sep 2015Dec 2015Mar 2016Jun 2016Sep 2016Dec 2016Mar 2017Jun 2017Sep 2017Dec 2017Mar 2018Jun 2018Sep 2018Dec 2018Mar 2019Jun 2019Sep 2019Dec 2019Mar 2020Jun 2020Sep 2020Mar 2021Jun 2021Sep 2021Mar 2022Jun 2022Sep 2022Mar 2023Jun 2023Sep 2023Mar 2024Jun 2024Sep 2024Mar 2025Jun 2025Sep 2025Mar 2026Jun 2026
Revenue 4.64B4.98B4.96B5.38B4.87B5.40B5.19B5.76B5.23B5.82B5.66B6.16B4.96B5.58B5.31B5.64B5.09B5.64B5.48B6.11B5.86B5.50B5.74B6.81B6.74B6.77B7.81B6.49B6.94B6.96B8.31B9.50B8.77B11.30B11.44B12.73B15.56B17.60B19.80B22.97B
Net Income 529.50M600.80M799.70M478.40M440.10M747.70M778.00M771.80M-110.80M1.01B555.60M-1.22B-259.90M1.15B-4.24B1.33B1.25B-1.46B1.41B1.21B1.36B1.39B1.11B1.90B952.50M1.45B1.34B1.76B-57.40M2.24B2.97B970.30M2.76B5.66B5.58B7.40B7.09B
Diluted EPS 0.500.560.750.450.410.710.730.73-0.100.950.53-1.581.16-0.251.121.104.311.441.371.641.601.551.331.491.531.222.101.051.611.491.95-0.062.483.281.073.066.296.218.267.94
R&D Expense 1.04B1.17B1.14B-1.22B1.34B1.24B-1.26B1.27B1.34B-1.11B1.27B1.28B-1.23B1.40B1.38B-1.39B1.39B1.47B1.67B1.66B1.71B1.61B1.78B1.80B1.99B2.36B---------

Profit & Loss (Annual)

Figures in USD.

Metric Dec 2007Dec 2008Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue 18.63B20.37B21.84B23.08B24.29B22.60B23.11B19.62B19.96B21.22B19.97B21.49B22.32B24.54B28.32B28.54B34.12B45.04B65.18B
Net Income 2.95B-2.07B4.33B5.07B4.35B4.09B4.68B2.39B2.41B2.74B-204.10M3.23B8.32B6.19B5.58B6.24B5.24B10.59B20.64B
Diluted EPS --1.893.944.583.903.664.322.232.262.58-0.193.138.896.796.126.905.8011.7122.95
R&D Expense 3.49B3.84B4.33B4.88B5.02B5.28B5.53B4.73B4.80B5.31B5.10B5.05B5.59B5.98B6.93B7.19B---

Balance Sheet (Annual)

Figures in USD.

Metric Dec 2006Dec 2007Dec 2008Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Total Assets --29.21B27.46B31.00B33.66B34.40B35.25B36.31B35.57B38.81B44.98B43.91B39.29B46.63B48.81B49.49B64.01B78.72B112.48B
Total Equity --6.74B9.53B12.42B13.54B14.77B17.63B15.37B14.57B14.01B11.59B9.83B2.61B5.64B8.98B10.65B10.77B14.27B26.54B
Cash & Equivalents 3.11B3.22B5.50B4.46B5.99B5.92B4.02B3.83B3.87B3.67B4.58B6.54B7.32B2.34B3.66B3.82B2.07B2.82B3.27B7.27B
Long Term Debt --4.62B6.63B6.77B5.46B5.52B4.20B5.33B7.97B8.37B9.94B9.20B13.82B16.59B15.35B14.74B18.32B28.53B40.87B
Current Liabilities --13.11B6.57B6.93B8.93B8.39B8.92B9.74B8.23B10.99B14.54B11.89B11.78B12.48B15.05B17.14B27.29B28.38B35.23B

Cash Flows (Annual)

Figures in USD.

Metric Dec 2007Dec 2008Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Operating Cash Flow 5.15B7.30B4.34B6.86B7.23B5.30B5.74B4.46B2.96B4.85B5.62B5.52B4.84B6.50B-7.59B4.24B8.82B16.81B
Investing Cash Flow -4.33B-7.27B142.80M-3.16B-4.82B-2.83B-2.07B-3.91B26.80M-3.14B-3.78B1.91B-8.08B-2.26B--3.76B-7.15B-9.30B-10.97B
Financing Cash Flow -844.90M2.35B-5.53B-2.02B-2.37B-4.42B-3.83B-166.40M-3.11B-559.80M142.60M-5.90B-2.32B-3.14B--5.41B3.50B1.23B-2.21B
Capital Expenditure ----------------2.99B-7.39B-8.40B-10.85B
Free Cash Flow ---------------4.60B-3.15B414.00M5.96B
Net Change in Cash ----------------1.58B583.00M746.00M3.63B
Share Buybacks ---00721.10M1.70B800.00M749.50M600.10M299.80M4.15B4.40B500.00M1.25B1.50B750.00M2.50B4.11B
Dividends Paid 1.85B2.06B2.15B2.17B2.18B2.19B2.12B2.10B2.13B2.16B2.19B2.31B2.41B2.69B3.09B3.54B4.07B4.68B5.38B

Ratios (Annual)

Figures in %.

Metric Dec 2007Dec 2008Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Gross Margin % -------------------
Operating Margin % -------------------
Net Margin % 15.8%-10.2%19.8%22.0%17.9%18.1%20.3%12.2%12.1%12.9%-1.0%15.0%37.3%25.2%19.7%21.9%15.4%23.5%31.7%
ROE % --30.8%45.4%40.8%32.1%27.7%26.6%15.5%16.5%19.5%-1.8%32.9%319.1%109.8%62.2%58.6%48.6%74.2%77.8%
ROCE % -------------------

Shareholding Pattern

Insiders
0.16%
Institutions
85.32%
Public Float
85.45%

Top Institutional Holders

#Holder% HeldSharesValue
1 Lilly Endowment, Inc 9.60% 90.38M $106.58B
2 Blackrock Inc. 7.17% 67.54M $79.65B
3 Vanguard Capital Management LLC 5.69% 53.53M $63.12B
4 PNC Financial Services Group, Inc. 5.45% 51.32M $60.52B
5 State Street Corporation 3.85% 36.22M $42.71B
6 FMR, LLC 3.02% 28.46M $33.56B
7 Capital Research Global Investors 2.22% 20.87M $24.62B
8 Vanguard Portfolio Management LLC 2.22% 20.86M $24.60B
9 Geode Capital Management, LLC 2.16% 20.31M $23.95B
10 Morgan Stanley 1.72% 16.23M $19.14B

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for LLY

Google News hu, 22 Oct 2026

Amgen vs. Eli Lilly: Does the GLP-1 Mania Make LLY Stock a Better Buy in 2026? - Yahoo Finance

<a href="https://news.google.com/rss/articles/CBMijAFBVV95cUxQM3lITDNTRlNvaml2ZzJST2ViZmdMTU5kR2loUkl4clBpRU8wWEdFRUpwUEEyaUtNWm50dThpd1NJZ0RhZkxfXzNWa3FmSTFiYm9HMVRmN1R3b29QVTVDbDBBZUVYOGdKM1ZPU2l2U19uZ0JpUUI1ZU9MbF9EalFQa0VKWjZEbERua3ZkMg…

Google News Wed, 21 Oct 2026

LLY Stock Alert: What to Know as Eli Lilly Hits a New All-Time High - Barchart.com

<a href="https://news.google.com/rss/articles/CBMirwFBVV95cUxOT0F6Q09SalVZYi1Cek44VnloRFlFWS04NHhwd2kwR3hUejJnYzg0RkxBandNODR6RlVfS1Rxa3ZzQnJSRE5yRXJyQl9URXBZMW9KT1o5eGZrUTgxWENrbFFUWUV4ekpGTGVNTk56M0ZnVENLUGF1RWJxdmdwX3EzTlhFSmJkT1FyLVd5SG…

Google News Wed, 21 Oct 2026

If You Invested $100 In Eli Lilly Stock 20 Years Ago, You Would Have This Much Today - Benzinga

<a href="https://news.google.com/rss/articles/CBMiuwFBVV95cUxQR0NDVV9MZmZIb1o5ODNNdGRoS2ZFZ2J0RVlUOEFDZGxJY2o5anlHNENTN3ItU2NJOUJxWEVMeDBleGRLYWpMMHhaanhaRS11MzZrSjJmNnktMTNHX0ZVcGhHcFJHQmg3aEg2SllxVEhPRXNwOWRub3ltVVg4ajRnaFRBMmczMFJyMFFZM1…

Google News ue, 20 Oct 2026

Eli Lilly (NYSE:LLY) Share Price, Forecast & Analysis - Stocks Down Under

<a href="https://news.google.com/rss/articles/CBMiWkFVX3lxTE5ZYlVURHkwQk9NZ29OWmp0U2dwT2REUzgxRGxzd2tvamVob2ZFMEpzS1pTZEVhR2F6NnQydmhjWXRUdW1VeE41VDhkYmdITWZfdWtYemwtV3N1QQ?oc=5" target="_blank">Eli Lilly (NYSE:LLY) Share Price, Forecast & …

Google News ue, 20 Oct 2026

Eli Lilly Stock (LLY) Hits All-Time High Ahead of Earnings - TipRanks

<a href="https://news.google.com/rss/articles/CBMijwFBVV95cUxQbm9nYXBEb3JYblUycTJySmNBWnBIYjE5bFdESmNzOVo1US1ITVRGZ25wSWlxbXg2T2pScGdELVliamdIMENTQTR3alpFdlQxdUtBVUhzNWx6N2V0U3EwWnNnUy1xMjZsbkI0eVg4a05lbTJIcng2RjNJT2Y5YUNLakJsLTE0dXJJbGFCLX…

Google News Mon, 19 Oct 2026

Prediction: Eli Lilly Stock Could Be a Long-Term Winner for Investors - 24/7 Wall St.

<a href="https://news.google.com/rss/articles/CBMisgFBVV95cUxQaUhzaFNudmtLMjhpdU1JcUdUdjZsN3pud3FMY0hVSFQzYmljazJ6bEV4dWVTV215MW9qcWNBazNFVUd1dXlHUzJTd3g3X2J6ek02WWNmSXFnYkxIa1RacHZxaDg2bWJETTZOVXVKZDFoZlBER2dScE1HWUxtaVdYUXFaQVA2cWJMZ0tDb2…

LLY — Frequently Asked Questions

What is the current share price of Eli Lilly and Company (LLY)?

As of 2026-10-22 16:30 PDT, Eli Lilly and Company (LLY) trades at $1,306.69 on NYSE. Its 52-week range is $655.85 to $1,306.69.

What is the market capitalisation of LLY?

Eli Lilly and Company (LLY) has a market capitalisation of $1.16T on NYSE.

What is the P/E ratio of LLY?

LLY trades at a trailing price-to-earnings (P/E) ratio of 43.95. The industry average P/E is 25.61. Its price-to-book (P/B) ratio is 30.34.

Does LLY pay a dividend?

Eli Lilly and Company (LLY) currently offers a dividend yield of 0.60%.

What is the return on equity (ROE) of LLY?

LLY has a return on equity (ROE) of 102.29%.

Is LLY a good stock to buy?

This page provides a data-driven analysis of Eli Lilly and Company (LLY), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks
⚙Ad space